Combining Cognitive Health with Physical Therapy For Holistic In-Clinic and Remote Rehabilitation with JJ Mosolf Academy Medtech Ventures TRANSCRIPT
Release Date: 04/08/2024
Deploying Technology in Decentralized Clinical Trials Improves Recruitment and Retention with Alice Lin Tigermed Consulting TRANSCRIPT
Empowered Patient Podcast
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize...
info_outline
Deploying Technology in Decentralized Clinical Trials Improves Recruitment and Retention with Alice Lin Tigermed Consulting
Empowered Patient Podcast
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize...
info_outline
Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics TRANSCRIPT
Empowered Patient Podcast
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our...
info_outline
Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics
Empowered Patient Podcast
Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle. Marshall explains, "Let me give you an example of our lead indication. So, our...
info_outline
Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT TRANSCRIPT
Empowered Patient Podcast
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any...
info_outline
Developing Drugs to Treat Rare Liver Diseases NASH PBC ACLF with Pascal Prigent GENFIT
Empowered Patient Podcast
Pascal Prigent, the CEO of GENFIT, a French biotech that has been working on liver diseases for about 20 years and has developed a compound called elafibranor for conditions such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and acute-on-chronic liver failure (ACLF). He highlights the high unmet medical need in ACLF, which currently has no approved treatment options and a high mortality rate. Prigent also discusses Genfit's partnership with Ipsen for the development and commercialization of elafibranor in PBC. Pascal explains, "In reality, we don't have any...
info_outline
Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPT
Empowered Patient Podcast
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form...
info_outline
Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates
Empowered Patient Podcast
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form...
info_outline
Preventative and Acute Treatment for Rare Genetic Disease HAE with Salome Juethner Takeda TRANSCRIPT
Empowered Patient Podcast
Salome Juethner, Senior Medical Director, Head of Rare Genetics, and Interim Head of Rare GI at Takeda, discusses HAE, hereditary angioedema, a rare genetic disorder that causes painful and unpredictable swelling attacks that can be life-threatening. Salome emphasizes the need to educate physicians to consider HAE as a potential diagnosis in children as young as two years old and underrepresented racial and ethnic groups. To treat HAE, Takeda offers Takhzyro, a medication that can be used on-demand and as a preventative therapy, administered at home through a subcutaneous injection. ...
info_outline
Preventative and Acute Treatment for Rare Genetic Disease HAE with Salome Juethner Takeda
Empowered Patient Podcast
Salome Juethner, Senior Medical Director, Head of Rare Genetics, and Interim Head of Rare GI at Takeda, discusses HAE, hereditary angioedema, a rare genetic disorder that causes painful and unpredictable swelling attacks that can be life-threatening. Salome emphasizes the need to educate physicians to consider HAE as a potential diagnosis in children as young as two years old and underrepresented racial and ethnic groups. To treat HAE, Takeda offers Takhzyro, a medication that can be used on-demand and as a preventative therapy, administered at home through a subcutaneous injection. ...
info_outlineJJ Mosolf, Founder and President of Academy Medtech Ventures, develops digital health solutions for use in clinical environments and at home to drive more effective rehabilitation. Addressing the brain and body by combining cognitive training with physical rehabilitation demonstrates better health outcomes and pain management. Their operating system, Cog PT, includes user-friendly tools for in-clinic assessment, AI human motion capture, and training, with a companion app for patients.
JJ explains, "We see the body and the brain as intricately connected. A lot of the literature over the past decade or so points to the brain as a vehicle for the upside, as the driving force behind what goes on from a neuromuscular standpoint. We see this less as, "Let's introduce cognition and neurocognitive training to uncover some deficiency or impairment," and more as a vehicle for training upside purposes. This connection point is typically where people struggle."
"The operating system term references every component within a clinical care instance. We recognize that it isn't just the delivery of a modality that a clinician cares about but the time that it takes to document said intervention and the ability to introduce connectivity to the home environment. We've tried to build a suite of tools to touch on each of those elements and provide the most easy-to-use and valuable service for clinicians, not just at the point of care."
"A tangible example would be the in-clinic modality side of what can be delivered as a software implementation on an iPad. It can be set up whether it's on a stand or in a patient's hands, and it fits within the workflow space. Then we've got some patient education tools and data tools to help on the workflow side, and the home remote monitoring side also rounds out the operating system. That's a core tenet of how we think about technological interventions in the rehab space."
#CognitiveTraining #AI #ComputerVision #Rehabilitation #PhysicalTherapy #Clinicians #DigitalHealth
